FRDA1 Gene - Frataxin (FXN)

FRDA1 - FXN (Frataxin)

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#f0f0f0; text-align:center;">FRDA1 Gene</th></tr> [@campuzano1996]
<tr><td><b>Official Symbol</b></td><td>FXN</td></tr> [@puccio2001]
<tr><td><b>Previous Symbol</b></td><td>FRDA</td></tr> [@campuzano1996]
<tr><td><b>Full Name</b></td><td>Frataxin</td></tr> [@pandolfo2014]
<tr><td><b>Chromosomal Location</b></td><td>9q21.11</td></tr> [@campuzano1996]
<tr><td><b>NCBI Gene ID</b></td><td>[2395](https://www.ncbi.nlm.nih.gov/gene/2395)</td></tr> [@puccio2001]
<tr><td><b>OMIM</b></td><td>[229300](https://www.omim.org/entry/229300)</td></tr> [@rotig1997]
<tr><td><b>UniProt ID</b></td><td>[Q16595](https://www.uniprot.org/uniprotkb/Q16595/entry)</td></tr> [@abrahams2019]
<tr><td><b>Protein Category</b></td><td>Mitochondrial Protein</td></tr> [@schmucker2008]
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Overview

FRDA1 - FXN (Frataxin)

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#f0f0f0; text-align:center;">FRDA1 Gene</th></tr> [@campuzano1996]
<tr><td><b>Official Symbol</b></td><td>FXN</td></tr> [@puccio2001]
<tr><td><b>Previous Symbol</b></td><td>FRDA</td></tr> [@campuzano1996]
<tr><td><b>Full Name</b></td><td>Frataxin</td></tr> [@pandolfo2014]
<tr><td><b>Chromosomal Location</b></td><td>9q21.11</td></tr> [@campuzano1996]
<tr><td><b>NCBI Gene ID</b></td><td>[2395](https://www.ncbi.nlm.nih.gov/gene/2395)</td></tr> [@puccio2001]
<tr><td><b>OMIM</b></td><td>[229300](https://www.omim.org/entry/229300)</td></tr> [@rotig1997]
<tr><td><b>UniProt ID</b></td><td>[Q16595](https://www.uniprot.org/uniprotkb/Q16595/entry)</td></tr> [@abrahams2019]
<tr><td><b>Protein Category</b></td><td>Mitochondrial Protein</td></tr> [@schmucker2008]
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Overview

The FRDA1 gene (officially symbol FXN) encodes frataxin, a small mitochondrial protein that plays a critical role in iron-sulfur cluster (Fe-S) biogenesis and mitochondrial iron homeostasis [@puccio2001]. Frataxin is essential for the assembly of Fe-S clusters, which serve as essential cofactors for numerous enzymes involved in oxidative phosphorylation, electron transport, and DNA repair. The discovery that GAA repeat expansions in the first intron of FXN cause Friedreich ataxia (FA) has made this gene a central focus of neurodegenerative disease research [@campuzano1996].

Friedreich ataxia is an autosomal recessive neurodegenerative disorder characterized by progressive ataxia, cardiomyopathy, diabetes mellitus, and loss of sensory function. The disease typically presents in childhood and leads to severe disability, with most patients becoming wheelchair-bound by their early twenties [@koeppen2018]. Understanding frataxin function has provided critical insights into mitochondrial dysfunction in neurodegeneration and has informed therapeutic development efforts.

Normal Function

Iron-Sulfur Cluster Biogenesis

Frataxin serves as the core scaffold protein for mitochondrial Fe-S cluster assembly [@schmucker2008]:

• Frataxin binds ferrous iron (Fe²⁺) with high affinity
• Forms a iron-loaded oligomeric complex
• Provides iron for cluster assembly on scaffold proteins

• Cooperates with ISCU (iron-sulfur cluster scaffold)
• Facilitates sulfur transfer from NFS1
• Enables rapid cluster formation and transfer

• Delivers assembled clusters to target proteins
• Supports multiple Fe-S enzyme maturation
• Requires interaction with ferredoxin

Mitochondrial Iron Homeostasis

Frataxin plays a crucial role in regulating mitochondrial iron levels [@puccio2001]:

• Iron import regulation: Controls mitochondrial iron uptake through MIYAML
• Iron storage coordination: Works with mitochondrial ferritin (FTMT)
• Prevents iron overload: Avoids toxic Fenton chemistry
• Protects against ferroptosis: Mitochondrial iron-mediated cell death

Expression Pattern

FXN is ubiquitously expressed with highest levels in:

• Heart: Highest expression - explains cardiac involvement
• Liver: High metabolic demand
• Kidney: Energy-intensive transport
• Brain: Dorsal root ganglia, cerebellum, spinal cord
• Skeletal muscle: High mitochondrial content

• [Dorsal root ganglia](/brain-regions/dorsal-root-ganglia) - highest
• [Cerebellum](/brain-regions/cerebellum) - Purkinje cells
• [Spinal cord](/brain-regions/spinal-cord) - anterior horn cells
• [Substantia nigra](/brain-regions/substantia-nigra) - dopaminergic neurons
• [Hippocampus](/brain-regions/hippocampus) - pyramidal neurons

Structure and Biochemistry

Protein Structure

Frataxin is a 210-amino acid protein with distinct domains [@abrahams2019]:

The protein forms a banana-shaped dimer that can further oligomerize in the presence of iron.

Iron Binding

• Binding sites: Multiple surface-exposed acidic residues
• Iron capacity: Up to 12 iron atoms per monomer
• Cooperativity: Iron binding shows positive cooperativity
• Dissociation constant: ~10⁻⁶ M for Fe²⁺

Oligomerization

• Iron-dependent assembly: Iron promotes higher-order oligomers
• Functional oligomers: Form larger complexes in vivo
• Phase separation: May form membrane-less organelles for cluster assembly

Disease Associations

Friedreich Ataxia

| Feature | Description |
|---------|--------------|
| Inheritance | Autosomal recessive |
| Prevalence | 1:50,000-1:40,000 |
| Onset | Childhood (5-15 years) |
| Core Symptoms | Ataxia, dysarthria, loss of proprioception |
| Additional Features | Cardiomyopathy, diabetes mellitus |
| GAA Repeat | 66-1700 repeats in intron 1 |

Pathogenesis

The GAA repeat expansion in FXN intron 1 causes:

• Forms triple-helix DNA structure
• Inhibits transcription elongation
• Reduces frataxin protein to 5-30% of normal

• Impaired Fe-S cluster assembly
• Reduced oxidative phosphorylation
• Energy deficit in high-demand tissues

• Mitochondrial iron accumulation
• Oxidative stress from Fenton chemistry
• Cellular toxicity

• Dorsal root ganglion degeneration
• Spinocerebellar tract damage
• Cardiomyocyte loss

Cardiomyopathy

Frataxin deficiency causes severe cardiac involvement [@strawinski2018]:

• Hypertrophic cardiomyopathy: Most common
• Dilated cardiomyopathy: In later stages
• Heart failure: Leading cause of mortality
• Arrhythmias: Including atrial fibrillation
• Sudden cardiac death: Risk in advanced disease

Diabetes Mellitus

Approximately 10-30% of FA patients develop diabetes [@lodi2015]:

• Mechanism: Pancreatic beta-cell dysfunction
• Correlation: Frataxin deficiency in pancreas
• Treatment: Insulin therapy often required
• Screening: Regular glucose monitoring essential

Neurodegeneration in Other Diseases

While FA is the primary disease, frataxin dysfunction may contribute to:

• Reduced frataxin in AD brain
• Mitochondrial dysfunction in AD neurons
• Iron dysregulation in AD

• Frataxin in dopaminergic neurons
• Mitochondrial vulnerability
• Iron accumulation in substantia nigra

• Mitochondrial dysfunction in motor neurons
• Energy deficit
• Oxidative stress

Molecular Mechanisms

Iron-Sulfur Cluster Assembly Pathway

The mitochondrial Fe-S cluster assembly (ISC) machinery includes [@vaidya2012]:

Pathogenic Cascade

Oxidative Stress

Frataxin deficiency leads to oxidative damage [@gomez2014]:

• Complex I deficiency: NADH:ubiquinone oxidoreductase
• Complex II deficiency: Succinate:ubiquinone oxidoreductase
• Aconitase inactivation: Iron-sulfur enzyme
• DNA damage: 8-oxoguanine accumulation

Metabolic Consequences

• Reduced ATP: 30-70% decrease in affected tissues
• Impaired glucose metabolism: Insulin resistance
• Fatty acid oxidation: Reduced beta-oxidation
• Apoptosis susceptibility: Increased cell death

Therapeutic Approaches

Current and Emerging Therapies

| Approach | Description | Status |
|----------|-------------|--------|
| Gene therapy | AAV-mediated FXN delivery | Phase I/II trials |
| RNAi silencing | Reduce toxic repeat transcripts | Preclinical |
| Iron chelation | Deferoxamine, deferasirox | Clinical trials |
| Antioxidants | CoQ10, idebenone | Approved in Europe |
| HDAC inhibitors | Increase frataxin expression | Clinical trials |
| Mitochondrial protectors | Pioglitazone | Phase II |

Gene Therapy

AAV vectors delivering functional FXN are in development [@colella2017]:

• Vectors: AAV9, AAVrh.10
• Delivery: Systemic, intracardiac, or intrathecal
• Dosing: Dose-escalation studies
• Endpoints: Safety and biomarkers
• Challenge: Achieving sufficient expression

Small Molecule Approaches

• HDAC inhibitors (vorinostat, panobinostat)
• Erythropoietin derivatives
• Bithionol

• Coenzyme Q10 + L-carnitine
• Idebenone (approved in Europe)
• Mitochondrial peptides

• Deferoxamine
• Deferasirox
• ICL670

Clinical Trials

Several trials are investigating FA therapies:

• AAV-FXN gene therapy (NCT04162288)
• Omaveloxolone (NCT02255435) - FDA approved
• Edaravone in FA (NCT03829514)
• Bithionol (NCT02780180)

Animal Models

Mouse Models

• Fxn knockout: Embryonic lethal
• Conditional knockouts: Tissue-specific deletion
• GAA knock-in: Mimics patient repeat
• Transgenic models: Human FXN expression

Zebrafish Models

• fxna/fxnb morphants: Developmental defects
• Mitochondrial dysfunction
• Cardiac abnormalities

In Vitro Models

• Patient-derived fibroblasts
• iPSC neurons
• Dorsal root ganglion cultures

Key Publications

See Also

• [Friedreich Ataxia](/diseases/friedreich-ataxia)
• [Spinocerebellar Ataxia](/diseases/spinocerebellar-ataxia)
• [Mitochondrial Disorders](/diseases/mitochondrial-disorders)
• [Iron-Sulfur Cluster Biogenesis](/mechanisms/iron-sulfur-cluster-biogenesis)
• [Hereditary Ataxia](/diseases/hereditary-ataxia)
• [Cardiomyopathy](/diseases/cardiomyopathy)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [NCBI Gene: FXN](https://www.ncbi.nlm.nih.gov/gene/2395)
• [UniProt: FXN (Q16595)](https://www.uniprot.org/uniprotkb/Q16595/entry)
• [OMIM: 229300](https://www.omim.org/entry/229300)
• [Ensembl: FXN](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000165060)
• [GeneReviews: Friedreich Ataxia](https://www.ncbi.nlm.nih.gov/books/NBK1281/)
• [Friedreich Ataxia Research Alliance](https://www.curefa.org/)

References